Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY450139 versus placebo for progression of Alzheimer's disease
2007-005118-37Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing LY450139 with Placebo (2 arms). Primary endpoints: ADAS-Cog11 change from baseline to endpoint and ADCS-ADL change from baseline to endpoint. Started Dec 2007; status: terminated.
02
Drugs
semagacestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2007-005118-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005118-37.